





# THE PROBLEM

 **30 millions**  
people in the world suffer  
**Advanced Diabetic Retinopathy**

 **1.5 millions**  
adults in the USA lose **Central Vision** due to  
**Macular Degeneration**

  
**Diabetic Retinopathy (DR)**

  
**Macular Degeneration (AMD)**




Cause of **visual dysfunction** and **blindness** in working-age adults




## OUR SOLUTION

Biopharmaceutical that acts in the:



- ✓ **INITIAL STAGE** of pathologies.
- ✓ **MORE EFFECTIVE.**
- ✓ **LESS INVASIVE** administration.

Our solution



-  *Blocks adverse effects*
-  *Preserves neuroprotective and neuroregenerative function*
-  *Long-lasting effect*

## MARKET



**Diabetic Retinopathy + Age-Related Macular Degeneration**

## FOUNDING TEAM



**Milagros Bürgi**  
CSO



**Ricardo Kratje**  
Scientific Board



**Marcos Oggero**  
Researcher



**Matías Depetris**  
Director & CEO

- Biotechnologist and PhD in Biological Sciences
- Expert in the development of biotherapeutics, cell cultures and immunology

- Biochemist, Pharmacist and PhD in Biochemistry
- Expert in Development of biotherapeutic/biosimilar production processes.
- Founder of Zelltek SA, now part of MegaLabs

- Biochemist and PhD in Biological Sciences
- Expert in Biotherapeutic Development and Glycoengineering

- Biotechnologist and PhD in Biological Sciences from UNL. MBA in progress.
- Expert in the production of biotherapeutics and pharmaceutical quality systems.

## ALLIANCES



## SEED INVESTMENT


**USD 1.5 millions**  
**25% equity**

**In the next 18 months**

**MILESTONE 1**  
GMP production process development and analytical development

**MILESTONE 2**  
Completion of Proof of Concept in animal models of retinopathies

**MILESTONE 3**  
Completion of preclinical trial (TRL 5)



**Contact:**  
Francisco Lozano Martínez  
flozano@newgenesis.cl

Raúl Vázquez Cassani  
rvazquez@newgenesis.cl